Business Combinations and Contingent Consideration (Tables)

3 Months Ended

Mar. 31, 2017

Talon Therapeutics, Inc. [Member]

Change in Fair Value of Contingent Consideration Related to Acquisitions

	Fair Value of Talon CVR
December 31, 2016	$	1,253
Fair value adjustment for the three months ended March 31, 2017	197
March 31, 2017	$	1,450

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following:

Cash consideration	$	3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$	7,700

Melphalan license [Member]

Change in Fair Value of Contingent Consideration Related to Acquisitions

	Fair Value of Ligand Contingent Consideration
December 31, 2015	$	5,227
Fair value adjustment for the three months ended March 31, 2016	773
Payment to Ligand in April 2016 for FDA approval milestone achievement	(6,000		)
December 31, 2016	$	—

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows:

IPR&D EVOMELA rights $ 7,700